Wayne Winegarden
Blog
State Leaders Admit California Is Subsidizing the Rich at the Expense of the Poor
You won’t read this headline anytime soon, but it is consistent with the recent changes to California’s electric-car rebate program enacted by the state’s Air Resources Board. Both California and the federal government offer generous tax credits to purchasers of electric vehicles. Until the recent changes, California offered purchasers of ...
Wayne Winegarden
December 10, 2019
Business & Economics
Want to end poverty in California? Embrace entrepreneurship.
Sacramento politicians have heralded the state’s record-low 4.0 percent unemployment figures. While this is good news, anyone living in Southern California will tell you that things aren’t as rosy as they appear to be. Take what’s going on in Imperial County, for example. Unemployment rates in the El Centro region, which borders ...
Wayne Winegarden
December 1, 2019
Blog
A Bearish View on California’s Budget Surplus
Last week the Legislative Analyst’s Office (LAO) published its latest fiscal outlook for California. The headlines were so great that you could almost hear the champagne corks popping in Sacramento. Not only has the state budget in California run surpluses for several years now, the LAO expects another surplus for ...
Wayne Winegarden
November 26, 2019
Drug Pricing
Wayne Winegarden Discusses Drug Price controls on Jim Bohannon Show
Wayne Winegarden, Director for PRI’s Center for Medical Economics and Innovation, discusses the many problems with drug price controls on the nationally syndicated Jim Bohannon Show.
Wayne Winegarden
November 13, 2019
Commentary
There Are High Costs From Implementing Drug Price Controls
Once wide coercive powers are given to government agencies…such powers cannot be effectively controlled. F.A. Hayek As part of the chorus calling for drug price controls, the New York Times editorial page has claimed that “Americans will need to accept a trade-off that other advanced nations long since come around to: Slightly ...
Wayne Winegarden
November 7, 2019
Business & Economics
NEW STUDY finds Overregulation Hurts Immigrant and Low-Income Entrepreneurs Trying to Achieve the American Dream
A new study released today by the nonpartisan Pacific Research Institute finds that government has erected barriers to opportunity that make it very difficult for immigrant and low-income entrepreneurs to lift themselves out of poverty and climb the economic ladder. Click here to download “Entrepreneurship as a Pathway to the ...
Wayne Winegarden
October 30, 2019
Commentary
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Wayne Winegarden
October 29, 2019
Commentary
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Wayne Winegarden
October 22, 2019
Climate Change
Policies Should Address Global Climate Change By Incenting Innovation
Amidst all of the rhetoric and dire predictions surrounding global climate change, it is easy to lose one’s perspective. But, we will not successfully minimize the risks created by global climate change without perspective. Fundamental to this perspective, U.S. greenhouse gas (GHG) emissions have been declining for more than a ...
Wayne Winegarden
October 4, 2019
Business & Economics
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Wayne Winegarden
October 2, 2019
State Leaders Admit California Is Subsidizing the Rich at the Expense of the Poor
You won’t read this headline anytime soon, but it is consistent with the recent changes to California’s electric-car rebate program enacted by the state’s Air Resources Board. Both California and the federal government offer generous tax credits to purchasers of electric vehicles. Until the recent changes, California offered purchasers of ...
Want to end poverty in California? Embrace entrepreneurship.
Sacramento politicians have heralded the state’s record-low 4.0 percent unemployment figures. While this is good news, anyone living in Southern California will tell you that things aren’t as rosy as they appear to be. Take what’s going on in Imperial County, for example. Unemployment rates in the El Centro region, which borders ...
A Bearish View on California’s Budget Surplus
Last week the Legislative Analyst’s Office (LAO) published its latest fiscal outlook for California. The headlines were so great that you could almost hear the champagne corks popping in Sacramento. Not only has the state budget in California run surpluses for several years now, the LAO expects another surplus for ...
Wayne Winegarden Discusses Drug Price controls on Jim Bohannon Show
Wayne Winegarden, Director for PRI’s Center for Medical Economics and Innovation, discusses the many problems with drug price controls on the nationally syndicated Jim Bohannon Show.
There Are High Costs From Implementing Drug Price Controls
Once wide coercive powers are given to government agencies…such powers cannot be effectively controlled. F.A. Hayek As part of the chorus calling for drug price controls, the New York Times editorial page has claimed that “Americans will need to accept a trade-off that other advanced nations long since come around to: Slightly ...
NEW STUDY finds Overregulation Hurts Immigrant and Low-Income Entrepreneurs Trying to Achieve the American Dream
A new study released today by the nonpartisan Pacific Research Institute finds that government has erected barriers to opportunity that make it very difficult for immigrant and low-income entrepreneurs to lift themselves out of poverty and climb the economic ladder. Click here to download “Entrepreneurship as a Pathway to the ...
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Policies Should Address Global Climate Change By Incenting Innovation
Amidst all of the rhetoric and dire predictions surrounding global climate change, it is easy to lose one’s perspective. But, we will not successfully minimize the risks created by global climate change without perspective. Fundamental to this perspective, U.S. greenhouse gas (GHG) emissions have been declining for more than a ...
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...